Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403J. Clin. Oncol 2020 Oct 06;[EPub Ahead of Print], SB Goldberg, MW Redman, R Lilenbaum, K Politi, TE Stinchcombe, L Horn, EH Chen, SH Mashru, SN Gettinger, MA Melnick, RS Herbst, MA Baumgart, J Miao, J Moon, K Kelly, DR Gandara
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.